Clinical Trials Browser

Phase 2 × Breast Neoplasms × tremelimumab × Clear all

NCT02536794 2022-05-17

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

30 enrolled 18 charts

Breast Neoplasms

NCT03608865 2022-01-03

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Phase 2 Completed

Breast Neoplasms

NCT02997995 2020-09-30

ULTIMATE

Phase 2 Completed

Breast Neoplasms